Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.
Hulin C et al.J Clin Oncol. 2016 Jun 20. pii: JCO667295. [Epub ahead of print].
A multicenter clinical study to determine the feasible initial dose of lenalidomide for maintenance therapy in patients with multiple myeloma following autologous peripheral blood stem-cell transplantation.
Yamamoto M et al. Mol Clin Oncol. 2016 Jun;4(6):965-970. Epub 2016 Mar 28.
Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myelomaand renal impairment.
Bridoux F et al. Cancer Chemother Pharmacol. 2016 Jul;78(1):173-182. Epub 2016 Jun 10.
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Siegel DS et al. Leuk Lymphoma. 2016 Jun 7:1-6. [Epub ahead of print].